HDAC6 and B-cell chronic lymphocytic leukemia: In contrast, the selective HDAC6 inhibitor rocilinostat (which belongs to class II HDAC inhibitors) or HDAC6-specific silencing is shown to cause the downregulation of PD-L1 in CLL patients [123].